Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E23.06 EPS (ttm)4.29 Insider Own0.10% Shs Outstand1.55B Perf Week3.14%
Market Cap153.41B Forward P/E11.05 EPS next Y8.94 Insider Trans-11.85% Shs Float1.55B Perf Month9.85%
Income6.82B PEG1.43 EPS next Q2.01 Inst Own74.30% Short Float2.09% Perf Quarter-6.77%
Sales30.95B P/S4.96 EPS this Y-2.40% Inst Trans-0.77% Short Ratio3.91 Perf Half Y-16.69%
Book/sh-2.15 P/B- EPS next Y13.68% ROA9.50% Target Price109.35 Perf Year41.46%
Cash/sh2.41 P/C40.99 EPS next 5Y16.12% ROE214.60% 52W Range69.47 - 125.86 Perf YTD2.17%
Dividend3.84 P/FCF25.15 EPS past 5Y1.20% ROI17.80% 52W High-21.49% Beta1.54
Dividend %3.89% Quick Ratio0.70 Sales past 5Y9.00% Gross Margin75.80% 52W Low42.23% ATR2.27
Employees29000 Current Ratio0.80 Sales Q/Q19.20% Oper. Margin32.80% RSI (14)60.20 Volatility2.06% 2.36%
OptionableYes Debt/Eq- EPS Q/Q5.40% Profit Margin20.70% Rel Volume0.76 Prev Close98.22
ShortableYes LT Debt/Eq- EarningsJul 27 BMO Payout72.90% Avg Volume8.30M Price98.81
Recom2.40 SMA205.05% SMA503.83% SMA200-1.57% Volume6,306,909 Change0.60%
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-17-18 05:00PM  3 Growth Stocks for Successful Investors Motley Fool
Aug-16-18 11:02AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COOL, TAL, FPI, ABBV and GDS GlobeNewswire
Aug-15-18 08:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV ACCESSWIRE
04:34PM  [$$] 5 Dividend Standouts Barrons.com
02:46PM  MARKETS: Bank of America is still bullish on US stocks long-termhere's why Yahoo Finance Video
Aug-14-18 06:01AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson Motley Fool
Aug-13-18 04:12PM  SHAREHOLDER ALERT: HAIR RMTI ABBV GDS NLSN ZN SBGI ORCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
02:22PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV PR Newswire
10:38AM  Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More Zacks
06:00AM  Why Enanta Stock Is Still a Strong Buy With Huge Upside InvestorPlace
Aug-12-18 11:45AM  SHAREHOLDER ALERT: MRCY GLNCY GLCNF MD FPI FIZZ SBGL ACAD ABBV TTPH RMTI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Aug-10-18 10:48AM  You Better Be Careful with Merck Stock, Especially at These Highs InvestorPlace
07:18AM  Jim Cramer Weighs In On Arch Coal, AbbVie And More Benzinga
Aug-09-18 07:05PM  Cramer Remix: Trade sanctions are hurting hedge funds the most CNBC
06:50PM  Cramer's lightning round: Coal may be in a renaissance, but don't buy the stocks CNBC
03:31PM  53 Best Dividend Stocks for 2018 and Beyond Kiplinger
01:21PM  NYSE trader: Expect stocks to churn this August Yahoo Finance Video
01:01PM  CLASS ACTION UPDATE for FPI and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Aug-08-18 08:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV ACCESSWIRE
04:23PM  Mylan Exploring Options As 'Unsustainable' Trends Hound Sales, Profit Investor's Business Daily
11:17AM  Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut Zacks
Aug-07-18 08:00AM  Express Scripts to Drop Big Sellers From AbbVie, Gilead in 2019 Bloomberg
06:33AM  Get Paid While You Wait: 3 Top Dividend Stocks in Healthcare Motley Fool
Aug-05-18 11:00AM  CLASS ACTION UPDATE for NWL, FLKS and ABBV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:31AM  Better Buy: Pfizer Inc. vs. AbbVie Inc. Motley Fool
Aug-01-18 12:39PM  Forget FAANGs, These Cos. Raised Dividends By 10% Investopedia
10:39AM  5 Retirement Stocks to Buy and Hold InvestorPlace
Jul-31-18 04:13PM  5 Top Stock Trades for Wednesday Is Procter Finally a Buy? InvestorPlace
03:41PM  SHAREHOLDER ALERT: MRCY HAIR TAL REVG GLCNF GLNCY FPI GOGO ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
11:27AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, DB, TTPH and ABBV GlobeNewswire
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV) PR Newswire
Jul-30-18 05:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV GlobeNewswire
05:02PM  CLASS ACTION UPDATE for ABBV, ORA and SBGL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:14PM  AbbVie's Stock Is Incredibly Cheap Motley Fool
08:31AM  Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know Motley Fool
08:00AM  Where to Find Bargains in the S&P 500 Investopedia
Jul-29-18 06:31AM  3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years Motley Fool
Jul-28-18 11:14AM  Edited Transcript of ABBV earnings conference call or presentation 27-Jul-18 1:00pm GMT Thomson Reuters StreetEvents
Jul-27-18 03:09PM  2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited Motley Fool
01:12PM  US STOCKS-Tech, healthcare stocks weigh on Wall Street Reuters
01:12PM  AbbVie cash cow Humira barely beats sales estimates, stock slides Reuters
11:43AM  Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod Zacks
11:11AM  AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up Zacks
10:30AM  How AbbVie Makes its Money Investopedia
08:50AM  AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates Zacks
08:01AM  AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up Zacks
07:53AM  AbbVie reports Q2 profit, revenue beats MarketWatch
07:38AM  AbbVie tops second-quarter estimates, sets higher earnings target Reuters
07:38AM  AbbVie Reports Second-Quarter 2018 Financial Results PR Newswire
02:45AM  Pharma Favorites: 7 Healthy Picks in the Drug Sector Investopedia
Jul-26-18 06:06PM  Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc. PR Newswire
03:47PM  A guide to biotechs building boom in South City American City Business Journals
02:13PM  AbbVie Q2 Earnings Preview Benzinga
07:55AM  ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions Zacks
Jul-25-18 01:10PM  3 'Strong Buy' Healthcare Stocks Poised to Surge TheStreet.com
12:24PM  AbbVie Secures FDA Approval for Endometriosis Drug Elagolix Zacks
09:29AM  In pursuit of Alzheimer's, cancer, growing Alector lands $133 million American City Business Journals
Jul-24-18 05:16PM  Citron's Left reiterates belief AbbVie shares will fall sharply Reuters
01:46PM  AbbVie prices new endometriosis drug at $10,000 a year Reuters
11:24AM  Merck (MRK) Q2 Earnings Coming Up: What's in the Cards? Zacks
11:20AM  AbbVie Wins U.S. Approval for Endometriosis Pain Treatment Bloomberg
10:56AM  Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings? Zacks
08:53AM  AbbVie wins FDA approval for oral treatment for endometriosis pain MarketWatch
08:30AM  AbbVie Receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis PR Newswire
07:58AM  What's in Store for Cardinal Health (CAH) in Q4 Earnings? Zacks
06:32AM  What to Expect When AbbVie Reports Q2 Earnings Motley Fool
Jul-23-18 05:47PM  Whats Next for Pfizer Stock After Being Called Out by President Trump InvestorPlace
03:05PM  With new attack on Alzheimer's, this young biotech is hiring, grabbing more space American City Business Journals
11:10AM  Healthcare ETFs to Buy on Solid Q2 Earnings Expectations Zacks
08:01AM  Better Buy: Gilead Sciences, Inc. vs. Celgene Motley Fool
06:33AM  AbbVie's Stock Is a Bargain After Falling 8% Last Week Motley Fool
Jul-22-18 07:30PM  The Global Cannabis Market Is Set To Explode Oilprice.com
05:24PM  Benzinga's Bulls & Bears Of The Week: AbbVie, Netflix, Philip Morris, Wells Fargo And More Benzinga
Jul-20-18 02:25PM  Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings? Zacks
08:59AM  Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals Zacks
08:00AM  Todays Research Reports on Stocks to Watch: eBay and AbbVie ACCESSWIRE
06:15AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-19-18 03:35PM  AbbVie Has Issues, But It Isn't the 'Next Big Drug Short' Bloomberg
01:53PM  Why AbbVie Shares Are Sliding Today InvestorPlace
12:03PM  AbbVie's Tumble May Not Last Barrons.com
11:58AM  AbbVie's Stock Hit By Citron Tweet Benzinga
11:17AM  3 Biotech Stocks to Watch This Quarter ACCESSWIRE
10:14AM  AbbVie shares drop 5.5% after short seller Citron calls it 'next great drug short' MarketWatch
09:45AM  Biogen (BIIB) to Report Q2 Earnings: What's in the Cards? Zacks
08:36AM  3 Big Stock Charts for Thursday: McDonalds, AbbVie and Coca-Cola InvestorPlace
Jul-18-18 01:38PM  Drugmakers Game the Patent System and Reap Billions, FDA Says Bloomberg
09:47AM  AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S. Zacks
Jul-17-18 08:46AM  Mylan signs U.S. license deal on Humira with AbbVie Reuters
08:05AM  AbbVie Announces HUMIRA® (adalimumab) Patent License with Mylan PR Newswire
Jul-15-18 06:32AM  3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-13-18 09:47AM  5 Big Pharma Stocks Investors Love Right Now InvestorPlace
08:51AM  Will J&J's (JNJ) Pharma Segment Strength Drive Q2 Earnings? Zacks
08:50AM  Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit Zacks
08:16AM  2 Overlooked Biotech Stocks to Buy Now Motley Fool
Jul-12-18 06:03PM  3 Pharma Stocks Goldman Sachs Sees as Buys TheStreet.com
09:42AM  AbbVie's Imbruvica Fails in Phase III Blood Cancer Study Zacks
09:29AM  J&J (JNJ) to Set Pharma Q2 Earnings in Motion: What's Up? Zacks
08:46AM  Keep Your Eyes on Healthcare's Odd Couple: AbbVie and Alphabet Motley Fool
08:37AM  Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial Benzinga
02:00AM  [$$] The drug pricing playbook: how pharma companies keep costs high Financial Times
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer ? Commercialization of Research; and the Universite de Montreal. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM